Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.54 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.46 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25557239 | 0.86 | OPRM1 (0.50) | OPRM1OPRD1OPRK1ALDH1A1 | |
| SCHEMBL1290759 | 0.84 | CYP3A4 (0.65) | OPRM1OPRD1OPRK1LMNACYP3A4 | |
| SCHEMBL6272646 | 0.83 | CYP3A4 (0.42) | CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL25879050 | 0.81 | OPRM1 (0.45) | OPRM1OPRD1OPRK1ALDH1A1 | |
| SCHEMBL31297843 | 0.81 | DDB1 (0.51) | ALDH1A1 | |
| SCHEMBL3724596 | 0.80 | OPRM1 (0.50) | OPRM1OPRD1OPRK1CHRM2CHRM4 | |
| SCHEMBL16549502 | 0.79 | OPRM1 (0.53) | OPRM1OPRD1OPRK1KCNA3CYP3A4 | |
| SCHEMBL24969422 | 0.78 | ALDH1A1 (0.46) | ALDH1A1 | |
| SCHEMBL1971471 | 0.77 | KMT2A (0.51) | LMNACYP2C19ALDH1A1 | |
| SCHEMBL25523481 | 0.77 | ALDH1A1 (0.49) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212172-A1 | ARYLACETAMIDE ANALOGS OF PIPERAZINE-[1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES | SAINT LOUIS UNIVERSITY | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212172-A1 | ARYLACETAMIDE ANALOGS OF PIPERAZINE-[1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES | AADAC, PAICS, PNPO | OPRM1 3913/4885OPRD1 4364/4885OPRK1 4202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.